Clinical Research Directory
Browse clinical research sites, groups, and studies.
The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.
Sponsor: Institute of Cancer Research, United Kingdom
Summary
BARCODE 1 is a screening study designed to investigate the role of genetic profiling for targeting population prostate cancer screening. A pilot of 300 men were recruited aiming to inform the feasibility and accessibility of the study approach. The full study is an extension of the pilot study aiming to recruit a total of 5000 men.
Official title: The BARCODE 1 Study: The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.
Key Details
Gender
MALE
Age Range
55 Years - 69 Years
Study Type
OBSERVATIONAL
Enrollment
4700
Start Date
2019-03-14
Completion Date
2028-12-31
Last Updated
2025-04-29
Healthy Volunteers
Yes
Conditions
Interventions
Genetic SNP profiling
Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
Prostate cancer screening
Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
MRI Scan
MRI scan will be offered to men identified within the top 10% genetic risk score profile.
Prostate biopsy
Transperineal prostate biopsy under local anaesthetic will be offered to men identified within the top 10% genetic risk score profile.
Locations (1)
Institute of Cancer Research and Royal Marsden Hospital
Sutton, Surrey, United Kingdom